Renal Biomarkers Market Expected to Expand at a Steady CAGR of 7.6% | Coherent Market Insights
SEATTLE, May 05, 2021, (PHARMIWEB) —
With the rising number of patients suffering from kidney diseases such as nephropathies, AKI (acute kidney injury), CKD (chronic kidney disease), and drug-induced kidney toxicities, novel renal biomarkers have been developed to help control disease progression rate. Renal biomarkers are used to distinguish renal injury from pre-, post-, and non-renal injury and to localize kidney injury (i.e., at the tubular level, glomerular level). These biomarkers can also be used to predict the seriousness of renal damage and monitor the progress of treatment.
In 2019, the global renal biomarkers market is expected to have a valuation of US$ 1,094.5 million and is projected to attain a valuation of US$ 1,894.2 million by 2027.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/3551
During the forecast period, the global renal biomarkers market is expected to rise due to rising demand for early disease detection of various kidney diseases. Renal biomarkers can help people with chronic kidney failure get an early diagnosis of kidney damage and learn more about the condition of their injury. These biomarkers may also predict the likelihood of disease progression, which aids in the advancement of customised medication for chronic kidney disease care.
During the forecast period, the use of renal biomarkers for the diagnosis of renal cancer is projected to provide lucrative growth opportunities for players in the global renal biomarkers industry. Renal biomarkers can be useful in the early detection of renal cancer. Many clinical and laboratory algorithms are currently in use, but there is no optimal method for the early detection of renal cancer and tumours that are believed to be discovered by mistake through routine abdominal imaging. Renal cancer should be detected early and treated before it progresses.
The global biomarker market is projected to be hampered by the lack of evidence of novel renal biomarkers and their failure to interact with clinical outcomes. The majority of renal biomarkers in use today elevate too late, making it difficult to link them to biologic or clinical outcomes. Furthermore, current renal biomarkers are more predictive of renal function than of renal injury, and are influenced by non-renal factors such as gender, age, and drug status, making acute kidney injury management more complex (AKI).
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3551
Various government agencies provide funding for research and development in the field of renal diseases. The National Institute of Diabetes and Digestive and Kidney Diseases, which is part of the Department of Health and Human Services’ National Institutes of Health, awarded Yale University a grant in September 2018 for the project “Identification of Non-invasive Biomarkers and Indices for Diagnosis of Drug-Induced Acute Interstitial Nephritis.”
The market’s growth is projected to be supported by research and development of biomarkers for kidney allergic reactions. Researchers from Johns Hopkins Medicine in the United States announced in May 2019 that they had identified two protein biomarkers in urine, Urine TNF- and IL-9’, which could be used to diagnose acute interstitial nephritis.
Key companies contributing in the global renal biomarkers market are Abbott Laboratories, Thermo Fisher Scientific Inc., Randox Laboratories Ltd., SphingoTec GmbH, Beckman Coulter, Inc., Astute Medical, Inc., and BIOPORTO A/S.
Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/3551
By Biomarker Type:
- Functional Biomarker
- Serum Creatinine
- Serum Cystatin C
- Urine Albumin
- Up-Regulated Proteins
- Neutrophil gelatinase-associated lipocalin
- Kidney injury molecule 1
- Interleukin 18
- Functional Biomarker
- Enzyme Linked Immunosorbent Assay
- Particle-Enhanced Turbidimetric Immunoassay
- Colorimetric Assay
- Chemiluminescent Enzyme Immunoassay
- Liquid Chromatography-Mass Spectrometry
By End User:
- Diagnostic Labs
- Outpatient Clinics
- Research Centers
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/renal-biomarkers-market-2870
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights,
1001 4th Ave,
#3200 Seattle, WA 98154, U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
- CDN Newswire